For the period October- December

  • Net sales for the period amounted to SEK 30.7 million (29.4).

  • Operating income (EBIT) for the period was SEK 9.5 million (2.2).

  • Operating margin for the period was 31 percent (8).

  • Earnings after tax for the period rose to SEK 7.2 million (0.1).

  • Earnings per share for the period, basic and diluted, was SEK 0.05 (0.02).

For the period January-December

  • Net sales for the year amounted to SEK 125.2 million (111.8).

  • Operating income (EBIT) for the year was SEK 22.9 million (9.6).

  • Operating margin for the year was 18 percent (9).

  • Earnings after tax for the year increased to SEK 15.2 million (2.3).

  • Earnings per share for the year, basic and diluted, was SEK 0.11 (0.05).

President and CEO Anders Karlsson’s commentary on 2014:
”In 2014, we worked successfully to improve our margins, and we report an operating margin of 18 percent for 2014 compared to 9 percent for 2013. We ended the year on a strong note, with an EBIT result of SEK 9.5 million in the fourth quarter. Turnover for 2014 as a whole increased by 12 percent, with stable growth in all product groups. Net sales growth was generated both in our established core markets in Europe and the USA, as well as from rising sales in new markets. Both sales and results also benefited from a weaker Swedish krona. We are now entering 2015 with a strong momentum and look forward to the launch of real-time PCR, a new platform for HLA typing, planned for the second half of the year.”

For more information please contact:

Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail: anders.karlsson@allenex.se
Yvonne Axelsson, CFO Allenex AB, and ph.: +468-508 939 72, e-mail: yvonne.axelsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on February 19, 2015, at 14.00 CET.
Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 55 persons are employed in the Allenex group.


About Us

LinkMed, in collaboration with innovators, develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in biotechnology and five in medical technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED). The company’s largest owners are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlöf. See www.linkmed.se for more information.

Documents & Links